Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here’s a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48% jump from last year. Revenue is seen skyrocketing 80% to $3.63 billion. Botox maker Allergan (AGN), which is fighting off a hostile takeover bid from Valeant (VRX), confirmed Monday that it had been
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week’s IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting earnings this week, including four pharma plays. Salix Pharmaceuticals (SLXP) has made headlines in recent months as both Allergan (AGN) and Actavis (ACT) have been rumored to be eyeing the gastrointestinal
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week’s IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting earnings this week, including four pharma plays. Salix Pharmaceuticals (SLXP) has made headlines in recent months as both Allergan (AGN) and Actavis (ACT) have been rumored to be eyeing the gastrointestinal